Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix, Inc. reports developments as a diagnostics solutions company focused on lung disease testing and biopharma development services. Its updates center on Diagnostic Tests such as Nodify Lung® Nodule Risk Assessment, Nodify CDT® and IQLung® Cancer Treatment Guidance, along with blood- and tissue-based testing, proteomic and genomic approaches, and development work for life sciences partners.
Recurring news also covers quarterly results, revenue guidance, test-volume trends, clinical validation studies, real-world evidence presentations at medical meetings, and the company’s efforts to expand evidence for lung nodule management and oncology testing applications.
Biodesix, a key player in lung disease diagnostics, has appointed Ryan Siurek as the new Chief Accounting Officer, reporting to CFO Robin Harper Cowie. Siurek brings extensive experience from Vail Resorts and Sprint Corporation, where he held significant accounting roles. His arrival is geared towards supporting the company's growth strategies for 2021 and beyond. Biodesix is recognized for innovative diagnostic tests that leverage AI, including its Lung Reflex® strategy and SARS-CoV-2 tests, aimed at expediting treatment decisions for lung disease patients.
Biodesix (Nasdaq: BDSX) has launched the ALTITUDE biomarker study, focusing on the clinical utility of the Nodify XL2 test for low to moderate risk lung nodules, in line with the 2018 ATS guidelines for lung cancer detection. Led by Dr. Gerard Silvestri, the randomized controlled trial aims to enroll 2,000 patients, with interim results expected in 2022 and study completion anticipated by late 2023. This initiative is part of Biodesix's commitment to enhancing lung disease diagnostics, leveraging AI and multi-omics technologies.
Biodesix reported record revenue of $9.2 million for Q3 2020, a 133% increase from the previous year, primarily driven by $5.5 million from COVID-19 diagnostic tests. The company completed a successful IPO, raising approximately $63 million. However, operating loss decreased to $6.2 million, down 31% year-over-year. Research expenses rose by 15%, while total cash reserves increased to $6.3 million as of September 30, 2020. The strategic partnership for COVID-19 testing further highlights the company’s role in the pandemic response.
Biodesix, Inc. (Nasdaq: BDSX) announced the publication of a study validating its Nodify XL2 lung nodule test. This test improves clinical decision-making by identifying patients with a low risk of malignancy, thereby reducing unnecessary invasive procedures. The research confirms the test’s accuracy with a sensitivity of 97% and negative predictive value of 98%. After two years, benign nodules remained benign, affirming its effectiveness over time. The study published in the CHEST Journal underscores Biodesix's commitment to enhancing patient outcomes.
Biodesix, Inc. (Nasdaq: BDSX) has successfully closed its initial public offering (IPO) of 4,000,000 shares at a price of $18.00 per share, raising approximately $72.0 million in gross proceeds. The shares began trading on The Nasdaq Global Market on October 28, 2020. Morgan Stanley and William Blair led the offering, with Canaccord Genuity and BTIG participating as managers. The offering's registration has been declared effective by the U.S. Securities and Exchange Commission. This announcement does not constitute an offer to sell or buy the securities.
Biodesix (Nasdaq: BDSX) announced the pricing of its initial public offering (IPO) of 4,000,000 shares at $18.00 per share. Trading on The Nasdaq Global Market is set to begin on October 28, 2020, with the IPO expected to close on October 30, 2020, pending customary closing conditions. Additionally, underwriters have a 30-day option to purchase up to 600,000 shares at the IPO price. Morgan Stanley and William Blair are the lead managers for this offering, which has been registered and declared effective by the U.S. Securities and Exchange Commission.